- Home
- NUVL vs ACT Comparison
NUVL vs ACT Comparison
Compare NUVL & ACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- ACT
- Stock Information
- Founded
- NUVL 2017
- ACT 1981
- Country
- NUVL United States
- ACT United States
- Employees
- NUVL N/A
- ACT N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- ACT Specialty Insurers
- Sector
- NUVL Health Care
- ACT Finance
- Exchange
- NUVL Nasdaq
- ACT Nasdaq
- Market Cap
- NUVL 5.8B
- ACT 5.5B
- IPO Year
- NUVL 2021
- ACT 2021
- Fundamental
- Price
- NUVL $80.89
- ACT $38.57
- Analyst Decision
- NUVL Strong Buy
- ACT Hold
- Analyst Count
- NUVL 11
- ACT 3
- Target Price
- NUVL $120.91
- ACT $39.67
- AVG Volume (30 Days)
- NUVL 429.4K
- ACT 258.2K
- Earning Date
- NUVL 08-07-2025
- ACT 07-30-2025
- Dividend Yield
- NUVL N/A
- ACT 2.22%
- EPS Growth
- NUVL N/A
- ACT 6.06
- EPS
- NUVL N/A
- ACT 4.41
- Revenue
- NUVL N/A
- ACT $1,223,030,000.00
- Revenue This Year
- NUVL N/A
- ACT $4.10
- Revenue Next Year
- NUVL N/A
- ACT $3.52
- P/E Ratio
- NUVL N/A
- ACT $8.56
- Revenue Growth
- NUVL N/A
- ACT 3.15
- 52 Week Low
- NUVL $55.54
- ACT $30.79
- 52 Week High
- NUVL $113.51
- ACT $38.87
- Technical
- Relative Strength Index (RSI)
- NUVL 61.76
- ACT 62.65
- Support Level
- NUVL $73.28
- ACT $36.93
- Resistance Level
- NUVL $81.10
- ACT $38.30
- Average True Range (ATR)
- NUVL 2.51
- ACT 0.60
- MACD
- NUVL 0.77
- ACT -0.02
- Stochastic Oscillator
- NUVL 83.27
- ACT 84.75
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers will be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.